Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 3
2008 4
2009 1
2010 2
2011 2
2012 2
2013 1
2014 1
2015 3
2016 2
2017 1
2018 1
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Population Pharmacokinetic Modeling of Dolutegravir to Optimize Pediatric Dosing in HIV-1-Infected Infants, Children, and Adolescents.
Chandasana H, Thapar M, Hayes S, Baker M, Gibb DM, Turkova A, Ford D, Ruel T, Wiznia A, Fairlie L, Bwakura-Dangarembizi M, Mujuru H, Alvero C, Farhad M, Hazra R, Townley E, Buchanan A, Bollen P, Waalewijn H, Colbers A, Burger D, Acosta EP, Singh R; IMPAACT P1093, ODYSSEY (PENTA 20) Study Teams. Chandasana H, et al. Among authors: alvero c. Clin Pharmacokinet. 2023 Oct;62(10):1445-1459. doi: 10.1007/s40262-023-01289-5. Epub 2023 Aug 21. Clin Pharmacokinet. 2023. PMID: 37603217 Free PMC article.
Etravirine in treatment-experienced HIV-1-infected children 1 year to less than 6 years of age.
MacBrayne CE, Rutstein RM, Wiznia AA, Graham B, Alvero CG, Fairlie L, Lypen K, George KH, Townley E, Moye J Jr, Costello DG, Reding CA, Barroso Hofer C, Crauwels HM, Woot de Trixhe X, Tambuyzer L, Vanveggel S, Opsomer M, Kiser JJ; and the IMPAACT P1090 Protocol Team. MacBrayne CE, et al. Among authors: alvero cg. AIDS. 2021 Jul 15;35(9):1413-1421. doi: 10.1097/QAD.0000000000002902. AIDS. 2021. PMID: 33831904 Free PMC article.
Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer.
Kastrinos F, Ojha RP, Leenen C, Alvero C, Mercado RC, Balmaña J, Valenzuela I, Balaguer F, Green R, Lindor NM, Thibodeau SN, Newcomb P, Win AK, Jenkins M, Buchanan DD, Bertario L, Sala P, Hampel H, Syngal S, Steyerberg EW; Lynch Syndrome prediction model validation study group. Kastrinos F, et al. Among authors: alvero c. J Natl Cancer Inst. 2015 Nov 18;108(2):djv308. doi: 10.1093/jnci/djv308. Print 2016 Feb. J Natl Cancer Inst. 2015. PMID: 26582061 Free PMC article.
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 Study.
Viani RM, Ruel T, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Palumbo P, Buchanan AM, Vavro C, Singh R, Graham B, Anthony P, George K, Wiznia A; P1093 Study Team. Viani RM, et al. Among authors: alvero c. J Pediatric Infect Dis Soc. 2020 Apr 30;9(2):159-165. doi: 10.1093/jpids/piy139. J Pediatric Infect Dis Soc. 2020. PMID: 30951600 Free PMC article. Clinical Trial.
Safety and efficacy at 240 weeks of different raltegravir formulations in children with HIV-1: a phase 1/2 open label, non-randomised, multicentre trial.
Nachman S, Alvero C, Teppler H, Homony B, Rodgers AJ, Graham BL, Fenton T, Frenkel LM, Browning RS, Hazra R, Wiznia AA; IMPAACT 1066 study team. Nachman S, et al. Among authors: alvero c. Lancet HIV. 2018 Dec;5(12):e715-e722. doi: 10.1016/S2352-3018(18)30257-1. Lancet HIV. 2018. PMID: 30527329 Free PMC article. Clinical Trial.
Insulin-like growth factor-1 and lean body mass in HIV-infected children.
Chantry CJ, Hughes MD, Alvero C, Cervia JS, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team. Chantry CJ, et al. Among authors: alvero c. J Acquir Immune Defic Syndr. 2008 Aug 1;48(4):437-43. doi: 10.1097/QAI.0b013e31817bbe6d. J Acquir Immune Defic Syndr. 2008. PMID: 18614924 Clinical Trial.
Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093.
Viani RM, Alvero C, Fenton T, Acosta EP, Hazra R, Townley E, Steimers D, Min S, Wiznia A; P1093 Study Team. Viani RM, et al. Among authors: alvero c. Pediatr Infect Dis J. 2015 Nov;34(11):1207-13. doi: 10.1097/INF.0000000000000848. Pediatr Infect Dis J. 2015. PMID: 26244832 Free PMC article. Clinical Trial.
22 results